Cannabis Science Updates Latest Remarkable Follow up Photographs Received from 3rd Cancer Patient

DENVER--(BUSINESS WIRE)--Jan 24, 2012 - Cannabis Science, Inc. (OTCBB: CBIS.OB) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to announce new remarkable photographic updates of the 3rd cancer patient, with treatment-resistant squamous cell carcinoma on his head.

Cannabis Science has been working with a number of self-medicated skin cancer patients, who are using cannabis-based extracts. Today Cannabis Science receives the latest photographs for the 3rd self-administering cancer patient, mentioned in the previous news release dated, January 11, 2012. The treatment process is ongoing, but the results have been visually dramatic, the cannabis extracts have drastically shrunk some tumors and others are gone.

You can view these graphic photos on the Cannabis Science website http://www.cannabisscience.com and click the button “View Images of 3rd Self-Medicated Patient & His Apparent Success”.

Cannabis Science is waiting for updated documentation and images on the 4th and 5th patient who are currently being treated with cannabis-based therapy. They are getting major results from the patients and couldn't be more pleased with the progress.

Cannabis Science is a patient oriented company. As such, we work closely with a number of patients suffering from a variety of illnesses. Because of its global impact on so many people, and often-poor treatment outcomes for patients, we have been focusing on cannabis extract-based treatment options for cancer. Cannabis Science has provided the scientific foundation for numerous patients suffering from cancer to make the informed decision to treat themselves with cannabis extracts.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

 

Contact: Cannabis Science Inc.
Dr. Robert J. Melamede, 1-888-889-0888
President & CEO
info@cannabisscience.com
www.cannabisscience.com
or
Robert Kane, 1-561-234-6929
Investor Relations Management
info@cannabisscience.com
www.cannabisscience.com

 

 

Posted: January 2012

View comments

Hide
(web3)